Could Ga-68 PSMA PET become essential for prostate cancer?
Coupling the radiopharmaceutical gallium-68 (Ga-68) prostate-specific membrane...Read more on AuntMinnie.comRelated Reading: Ga-68 PSMA PET/CT for prostate wins Australian favor Ga-68 PSMA-11 PET/MRI improves prostate cancer detection Ga-68 PSMA-11 PET/MRI benefits prostate cancer patients Ga-68 PSMA-11 PET/MRI advances prostate cancer detection Gallium-labeled PET tracer could advance cancer detection
Prostate cancer is the most prevalent cancer among men, with an estimated 175,000 new diagnoses in the United States in 2019. A variety of treatment options are available, including active surveillance, radiation therapy, or radical prostatectomy. The choice of treatment modality is based on a number of considerations: risk group, age, comorbidities, and performance status. Shared decision making and informed consent plays a pivotal role in the type of treatment a patient pursues. Patients must understand not only the cancer-related outcomes for their particular situation, but also the anticipated side effects of treatment.
PROSTATE cancer is the most common cancer in men in the UK. As the condition develops slowly, there may be no signs for many years. One warning sign can be seen at night.
Publication date: Available online 21 October 2019Source: Carbohydrate PolymersAuthor(s): Ding Qu, Mengying Jiao, Haijiao Lin, Chunli Tian, Guowei Qu, Jingwei Xue, Lingjing Xue, Caoyun Ju, Can ZhangAbstractControlled release and tumor-selective distribution are highly desirable for anticancer nanomedicines. Here, we design and synthesize an anisamide-conjugated N-octyl-N,O-maleoyl-O-phosphoryl chitosan (a-OMPC) which can form amphiphilic micelles featuring pH-responsive release and high affinity to sigma-1 receptor-overexpressed tumors for paclitaxel (PTX) delivery. Thereinto, maleoyl and phosphoryl groups cooperatively co...
ConclusionsUse of the nuclear-localized AR-V7 CTC test to inform treatment choice can improve patient outcomes relative to decisions based solely on standard-of-care measures.Patient summaryMen with metastatic prostate cancer who test positive for AR-V7 protein in circulating tumor cells are likely to live longer if taxane chemotherapy is used.
Conditions: Positive Lymph Node; Prostate Adenocarcinoma; PSA Level Greater Than Zero; Stage I Prostate Cancer AJCC v8; Stage II Prostate Cancer AJCC v8; Stage IIA Prostate Cancer AJCC v8; Stage IIB Prostate Cancer AJCC v8; Stage IIC Prostate Cancer AJCC v8; Stage III Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage I...
Conditions: Metastatic Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8 Interventions: Procedure: Computed Tomography; Drug: Fluciclovine F18; Procedure: Positron Emission Tomography Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI) Recruiting
Condition: Prostate Cancer Recurrent Interventions: Drug: Degarelix 120 MG [Firmagon]; Drug: Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector; Drug: Testosterone Undecanoate Sponsors: Lund University; Swedish Cancer Foundation; ALF Swedish Government Grant Recruiting
BILL TURNBULL, best known for being a presenter on BBC Breakfast, revealed he was diagnosed with prostate cancer in 2017. As part of a new documentary airing this week, the journalist opens up about his treatment and how his life has changed since the diagnosis.
A comparison of two gadolinium-based contrast agents (GBCAs) for hepatobiliary...Read more on AuntMinnie.comRelated Reading: Ga-68 PSMA PET/MRI, mpMRI work for prostate cancer analysis Study shines more light on GBCA-related adverse reactions Gadolinium in gliomas, adjacent tissue raises questions German study may offer new way to detect gadolinium FDA adds 8 gadolinium MRI agents to medication guide
ConclusionsModerately hypofractionated RT with HT for localized prostate cancer reported excellent outcomes with mild acute and late toxicity incidence, with promising biochemical control rates.